BCYP News and Press, SAB Biotherapeutics Inc Com From 09/22/21

$200 million total awarded to date for DiversitAb™ Rapid Response Antibody Program including Stage 4 COVID-19 Pandemic Response Expanded contract scope includes commercial manufacturing and clinical development through licensure for SAB-185 for the treatment of COVID-19...

Topline data expected in 4Q2021 SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced t...

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that Eddie J. Sullivan, PhD, co-founder, pres...

FDA findings from research published in bioRxiv using in vitro pseudovirus models confirm SAB-185 broadly neutralizes variants of concern SAB-185 currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial SAB Biotherapeutics (SAB), a clinical-stage biopharma...

Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics PR Newswire MIAMI , July 15, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a blank check company focus...

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics, today announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will pre...

Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination with SAB Biotherapeutics PR Newswire MIAMI , July 7, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Bi...

7 new deals and 7 SPAC business combinations announced last week. Lydall stock jumps 85% after news of acquisition. Buzzfeed to go public in a SPAC deal. For further details see: Merger Arbitrage Mondays - Buzzfeed To Go Public With 890 Fifth Avenue Partners

SAB Biotherapeutics (SAB) has entered into a definitive merger agreement with Big Cypress Acquisition Corp. (NASDAQ: BCYP) and upon closing, the combined company is expected to be listed on NASDAQ Anticipated resources post-transaction will be used to further expand the new ...

MIAMI, FL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Big Cypress Acquisition Corp. (the "Company") announced that, commencing February 9, 2021, holders of the units sold in the Company's initial public offering of 11,500,000 units may elect to separately trade the shares of common stock and red...